78155-74-5

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 5-bromo-1H-indazole-3-carboxylate is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs. Its unique structural properties and reactivity make it a promising candidate in medicinal chemistry for creating novel therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 5-bromo-1H-indazole-3-carboxylate is utilized as an intermediate in the production of pesticides. Its chemical properties allow for the creation of effective compounds aimed at controlling pests and enhancing crop protection.
Used in Research and Laboratory Experiments:
Methyl 5-bromo-1H-indazole-3-carboxylate also serves as a building block for the synthesis of other organic compounds in research and laboratory settings. Its versatility in chemical reactions facilitates the exploration of new chemical pathways and the discovery of innovative organic compounds with potential applications across various fields.

InChI:InChI=1/C9H7BrN2O2/c1-14-9(13)8-6-4-5(10)2-3-7(6)11-12-8/h2-4H,1H3,(H,11,12)

Upstream product

• 1077-94-7 5-bromobenzopyrazole-3-carboxylic acid 
• 67-56-1 methanol 
• 87-48-9 5-Bromo-1H-indole-2,3-dione 
• 201230-82-2 carbon monoxide 
• 459133-66-5 5-bromo-3-iodo-1H-indazole 
• 4498-67-3 1H-Indazole-3-carboxylic acid 
• 43120-28-1 methyl 1H-indazole-3-carboxylate 

Downstream Products

• 936132-61-5 5-bromo-3-formyl-indazole-1-carboxylic acid tert-butyl ester 
• 936132-62-6 3-(2-benzyloxycarbonylamino-2-methoxycarbonyl-vinyl)-5-bromo-indazole-1-carboxylic acid tert-butyl ester 
• 705264-93-3 (5-bromo-1H-indazol-3-yl)methanol 
• 1363381-41-2 5-bromo-1-methyl-1H-indazole-3-carboxylic acid methyl ester 
• 1630906-74-9 methyl 5-bromo-2-methyl-2H-indazole-3-carboxylate 

Relevant academic research and scientific papers

Heteroaromatic ring compound and application thereof

The invention relates to a heteroaromatic ring compound and application thereof. Specifically, the invention provides a compound shown as a formula I, or an optical isomer or raceme thereof, or a pharmaceutically acceptable salt thereof. The compound prov

5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

INDAZOLE CONTAINING MACROCYCLES AND THERAPEUTIC USES THEREOF

Indazole macrocycle compounds of formula (I) for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole macrocycle compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. Formula (I)

Indazol-carboxamide-pyridinone derivatives as well as preparation method and applications thereof

The invention belongs to the field of chemical medicine preparation, and concretely relates to indazol-carboxamide-pyridinone derivatives, a preparation method and applications thereof. The inventionprovides the indazol-carboxamide-pyridinone derivatives, and a structure is represented by a formula I. The present invention also provides the preparation method and the applications of the above indazol-carboxamide-pyridinone derivatives. The indazol-carboxamide-pyridinone derivatives provided by the invention are novel compounds obtained on the basis of a large number of screening, inhibit EZH2activity, and provide a novel selection for development and application of medicines for resisting tumors and autoimmune diseases.

METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF

Provided is a compound superior in an autotaxin inhibitory action and the like, effective as a prophylactic or therapeutic drug for diseases involving ATX. The present invention relates to a compound represented by the following formula (I): [wherein each symbol is as described in the DESCRIPTION], which has a superior autotaxin inhibitory action and is useful as a prophylactic or therapeutic drug for diseases involving ATX.

SUBSTITUTED INDAZOLES AND RELATED HETEROCYCLES

The present invention relates to substituted indazoles and related heterocycles. These compounds are useful for the prevention and/or treatment of hyperproliferative, inflammatory and degenerative disorders and diseases. Thus, this invention is also concerned with the use of the compounds of the present invention for the the prevention and/or treatment of hyperproliferative, inflammatory and degenerative disorders and diseases as well as pharmaceutical composition, medicaments and kits comprising the substituted indazoles and related heterocycles of the present invention and processes for manufacturing those compounds.

5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, and neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.